Sevofluorane

ApprovedSmall molecule

TTamas Vegh, MD

Sevofluorane is one of 5 small molecule programs targeting Agitation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CraniosynostosisActive, not recruiting

CraniosynostosisApproved

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Craniosynostosis

#DrugCompanyPhaseTrials

Sevofluorane

TTamas Vegh, MD

Approved

1 2

Low Dose TXA

BBoston Children's Hospital

Approved

1 3

High Dose TXA

BBoston Children's Hospital

Approved

1 4

Cyklokapron

AAmring

Preclinical

1 5

Ferrous Fumarate or Ferrostrane

UUniversity Hospital, Montpellier

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Craniosynostosis1 trial

Measuring of the Duration of Action of Different Doses of Rocuronium-induced Neuromuscular Block in Infants During Surgical Treatment of Craniosynostosis

Enrolling by invitation·TTamas Vegh, MD·Phase 4·NCT07080528·20 enrolled

Mitral Valve Surgery1 trial

Preconditioning With Sevoflurane and Propofol in Patients Undergoing Minimally Invasive Mitral Valve Surgery

Unknown status·FFondazione Toscana Gabriele Monasterio··NCT02551328·48 enrolled

Inhalational Anesthesia1 trial

Effect of Combined Intravenous-Inhalational Anesthesia (CIVIA) on Postoperative Recovery Patterns.

Recruiting·—·Phase 4·NCT07123870·210 enrolled

Agitation1 trial

The Effect of Induction Technique on Postoperative Pain and Agitation

Completed·MMustafa Kemal University·Phase 4·NCT02110745·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sevofluorane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sevofluorane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sevofluorane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tamas Vegh, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTamas Vegh, MD

Sevofluorane

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Craniosynostosis1 trial

Mitral Valve Surgery1 trial

Inhalational Anesthesia1 trial

Agitation1 trial

References

Drug Info

Quick Facts

Related News